[(2H-1,3-benzodioxol-5-yl)methyl](butyl)amine | 68291-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: [(2H-1,3-benzodioxol-5-yl)methyl](butyl)amine
• 英文别名: N-(1,3-benzodioxol-5-ylmethyl)butan-1-amine
• CAS: 68291-94-1
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD07409924
• 分子量: 207.272
• InChiKey: KROMMYPARAZRAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  296.4±9.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二甲基异氰酸苯酯 、 [(2H-1,3-benzodioxol-5-yl)methyl](butyl)amine 以 正己烷 为溶剂， 以97%的产率得到N-[(2H-1,3-Benzodioxol-5-yl)methyl]-N-butyl-N'-(2,4-dimethylphenyl)urea
  参考文献：
  名称：

  潜在的抗动脉粥样硬化剂。6.降胆固醇的三取代尿素类似物。

  摘要：

  一系列N，N-二烷基-N'-芳基脲是ACAT酶的抑制剂的发现导致了结构活性研究，涉及系统修饰尿素主链的三个位点。这项研究最终选择了N'-（2,4-二甲基苯基）-N-苄基-Nn-丁基脲（115），以进行更广泛的生物学评估。ACAT抑制剂被视为对抗高胆固醇血症和动脉粥样硬化的潜在有益药物。

  DOI：

  10.1021/jm00130a016
• 作为产物：
  描述：

  胡椒酸 在 盐酸 、 三氟化硼乙醚 、 硼烷 、 三乙胺 作用下， 以 甲苯 为溶剂， 生成 [(2H-1,3-benzodioxol-5-yl)methyl](butyl)amine
  参考文献：
  名称：

  潜在的抗动脉粥样硬化剂。6.降胆固醇的三取代尿素类似物。

  摘要：

  一系列N，N-二烷基-N'-芳基脲是ACAT酶的抑制剂的发现导致了结构活性研究，涉及系统修饰尿素主链的三个位点。这项研究最终选择了N'-（2,4-二甲基苯基）-N-苄基-Nn-丁基脲（115），以进行更广泛的生物学评估。ACAT抑制剂被视为对抗高胆固醇血症和动脉粥样硬化的潜在有益药物。

  DOI：

  10.1021/jm00130a016

文献信息

• [EN] NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS<br/>[FR] ARYL IMIDAZOLES ET COMPOSES ASSOCIES, MODULATEURS DE RECEPTEUR C5A
  申请人：NEUROGEN CORP

  公开号：WO2003082829A1

  公开（公告）日：2003-10-09

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula (I) where the ring system represented by Formula (A) is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar1, Ar2, R, R1, R2, R3, R4, R5, R6, y and z are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  该发明提供了式（I）中的芳基取代咪唑、吡唑、吡啶和相关化合物，其中由式（A）表示的环系统是一个5成员杂芳基环系统，在该环系统中x为0，A从碳和杂原子氮、氧和硫中选择，E和G分别为碳或氮，前提是5成员杂芳基环系统不含超过3个杂原子或超过1个氧或硫原子，或者是一个6成员杂芳基环系统，在该环系统中x为1，A、B、E和G分别从碳和氮中选择，前提是6成员杂芳基环系统不含超过3个氮原子。其余变量Ar1、Ar2、R、R1、R2、R3、R4、R5、R6、y和z在此处定义。这些化合物是C5a受体的配体。该发明的优选化合物具有高亲和力结合到C5a受体，并且在C5a受体上表现为中性拮抗剂或逆激动剂活性。该发明还涉及包含这些化合物的药物组合物。它进一步涉及使用这些化合物治疗各种炎症和免疫系统疾病。
• Synthesis and Evaluation of 6-Nitro-7-(1-piperazino)quinazolines: Dual-Acting Compounds with Inhibitory Activities toward Both Tumor Necrosis Factor-.ALPHA. (TNF-.ALPHA.) Production and T Cell Proliferation
  作者：Masanori Tobe、Yoshiaki Isobe、Hideyuki Tomizawa、Takahiro Nagasaki、Masamitsu Aoki、Toru Negishi、Hideya Hayashi

  DOI：10.1248/cpb.51.1109

  日期：——

  We investigated the chemical modifications of the nitroquinazoline derivative (1) through the replacement of the NH group at the C(4)-position with several N-alkyl groups to increase the lipophilicity at the C(4)-position. Among them, we found that the N-methyl analogue (5a) showed a 2-fold loss in the inhibitory activity toward tumor necrosis factor-α (TNF-α) production in vitro as compared with the NH analogue (1); however, 5a exhibited an oral inhibitory activity on TNF-α production with an ED50 value of 26 mg/kg, whereas 1 did not. Moreover, the oral bioavailability of 5a was higher than that of 1 (1, F=1%; 5a, F=21%), and the calculated ClogP value for 5a was higher than that for 1. These results suggest that the improved lipophilicity of 5a compared with that of 1 reflects its greater inhibitory activity on TNF-α production in vivo as well as oral bioavailability.

  我们研究了硝基喹唑啉衍生物（1）的化学修饰，通过用几个 N-烷基取代 C(4)-位上的 NH 基团来增加 C(4)-位上的亲油性。其中，我们发现与 NH 类似物（1）相比，N-甲基类似物（5a）对肿瘤坏死因子-α（TNF-α）生成的体外抑制活性降低了 2 倍；但是，5a 对 TNF-α 生成具有口服抑制活性，ED50 值为 26 mg/kg，而 1 则没有。此外，5a 的口服生物利用度高于 1（1，F=1%；5a，F=21%），5a 的计算 ClogP 值也高于 1。这些结果表明，与 1 相比，5a 的亲脂性更强，这反映了它对 TNF-α 在体内产生的抑制活性以及口服生物利用度更高。
• New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators
  申请人：Luke P. George

  公开号：US20070208048A1

  公开（公告）日：2007-09-06

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the ring system represented by is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar 1 , Ar 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  本发明提供了Aryl取代的咪唑、吡唑、吡啶并相关化合物的公式，其中由环系表示的是一个5元杂环芳基环系，其中x为0，A选择自碳和杂原子氮、氧和硫，而E和G独立地为碳或氮，但5元杂环芳基环系不含有超过3个杂原子或超过1个氧或硫原子，或者是一个6元杂环芳基环系，其中x为1，A、B、E和G独立地选择自碳和氮，但6元杂环芳基环系不含有超过3个氮原子。其余变量Ar1、Ar2、R、R1、R2、R3、R4、R5、R6、y和z在此定义。这些化合物是C5a受体的配体。本发明的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这种化合物的制药组合物。它还涉及使用这些化合物治疗各种炎症和免疫系统疾病。
• Benzimidazole derivatives and their use as a medicament
  申请人：Poitout Lydie

  公开号：US20090170922A1

  公开（公告）日：2009-07-02

  A subject of the present application is new benzimidazole derivatives of formula in which A, Y, R 1 , R 2 , R 3 and R 4 represent different variable groups. These products have an antagonist activity of GnRH (Gonadotropin-Releasing Hormone). The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

  本申请的主题是公式中A、Y、R1、R2、R3和R4代表不同变量基团的新苯并咪唑衍生物。这些产物具有GnRH（促性腺激素释放激素）的拮抗活性。本发明还涉及含有所述产物的制药组合物及其用于制备药物的用途。
• Synthesis of Amines by the Intermolecular Schmidt Reaction of Aliphatic Azides with Carbocations
  作者：William H. Pearson、Wen-kui Fang

  DOI：10.1021/jo00121a001

  日期：1995.8